Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 82854-37-3
2. Dsstox_cid_13469
3. Chebi:4745
4. I04o1dt48t
5. [(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
6. Ac1nqz1q
7. Unii-i04o1dt48t
8. Echinacoside,(s)
9. Mfcd00075695
10. Surecn525502
11. Dsstox_rid_79077
12. Dsstox_gsid_33469
13. Echinacoside [usp-rs]
14. Echinacoside, 98% (hplc)
15. Schembl525502
16. Chembl510539
17. Megxp0_001773
18. Dtxsid0033469
19. Echinacoside, Analytical Standard
20. Hms3885k04
21. Hy-n0020
22. Tox21_200945
23. S3783
24. Zinc85504689
25. Akos015897141
26. Ccg-270479
27. Cs-3400
28. Db15488
29. Ncgc00091915-01
30. Ncgc00091915-02
31. Ncgc00258498-01
32. Ac-34699
33. As-56376
34. Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl O-6-deoxy-alpha-l-mannopyranosyl-(1-3)-o-(beta-d-glucopyranosyl-(1-6))-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate), Beta-d-
35. Cas-82854-37-3
36. A12039
37. 854e373
38. Q475631
39. Echinacoside, Primary Pharmaceutical Reference Standard
40. Echinacoside, United States Pharmacopeia (usp) Reference Standard
41. (2r,3r,4r,5r,6r)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-((((2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)methyl)-4-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)tetrahydro-2h-pyran-3-yl 3-(3,4-dihydroxyphenyl)acrylate
42. .beta.-d-glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl O-6-deoxy-.alpha.-l-mannopyranosyl-(1->3)-o-(.beta.-d-glucopyranosyl-(1->6))-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate)
43. [(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxymethyl]-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-tetrahydropyran-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
44. 2-(3,4-dihydroxyphenyl)ethyl 6-deoxy-alpha-l-mannopyranosyl-(1-3)-[beta-d-glucopyranosyl-(1-6)]-4-o-[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-d-glucopyranoside
45. 3,4-dihydroxyphenethyl 3-o-(alpha-l-rhamnopyranosyl)-4-o-(3,4-dihydroxycinnamoyl)-6-o-(beta-d-glucopyranosyl)-beta-d-glucopyranoside
46. 737806-07-4
47. Echinacoside (ang, Pal) (constituent Of Echinacea Angustifolia Root, Echinacea Pallida Root, Echinacea Purpurea Root And Echinacea Purpurea Aerial Parts) [dsc]
48. Ncgc00091915-03![(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Molecular Weight | 786.7 g/mol |
---|---|
Molecular Formula | C35H46O20 |
XLogP3 | -2.1 |
Hydrogen Bond Donor Count | 12 |
Hydrogen Bond Acceptor Count | 20 |
Rotatable Bond Count | 14 |
Exact Mass | 786.25824385 g/mol |
Monoisotopic Mass | 786.25824385 g/mol |
Topological Polar Surface Area | 324 Ų |
Heavy Atom Count | 55 |
Formal Charge | 0 |
Complexity | 1230 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 15 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Absorption
Animal studies suggest an oral bioavailability of 0.83%.
The metabolism of echinacoside has been investigated in rats and is thought to involve catechol O-methyltransferase as well as unspecified UDP-gluc- uronosyltransferases and sulfotransferases. A study of echinacoside's metabolism by human intestinal flora identified 13 metabolites which are produced independantly of human metabolism.
The neuroprotective effects are thought to be mediated via effects on mitogen-activated protein kinase, nuclear factor kappa-B, caspases 3 and 8, as well as CHOP pathways.
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Echinacoside manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Echinacoside, including repackagers and relabelers. The FDA regulates Echinacoside manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Echinacoside API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Echinacoside supplier is an individual or a company that provides Echinacoside active pharmaceutical ingredient (API) or Echinacoside finished formulations upon request. The Echinacoside suppliers may include Echinacoside API manufacturers, exporters, distributors and traders.
Echinacoside Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Echinacoside GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Echinacoside GMP manufacturer or Echinacoside GMP API supplier for your needs.
A Echinacoside CoA (Certificate of Analysis) is a formal document that attests to Echinacoside's compliance with Echinacoside specifications and serves as a tool for batch-level quality control.
Echinacoside CoA mostly includes findings from lab analyses of a specific batch. For each Echinacoside CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Echinacoside may be tested according to a variety of international standards, such as European Pharmacopoeia (Echinacoside EP), Echinacoside JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Echinacoside USP).
LOOKING FOR A SUPPLIER?